The Trump administration on Wednesday issued new rules that will put some foreign investment in U.S. biotech under heightened scrutiny, a sweeping measure that comes as Asian investors pour billions into stateside drug developers.

Biotech is among 27 industries subject to Treasury Department rules, which mandate that foreign investments in “critical technologies” undergo review by the Committee on Foreign Investment in the U.S., or CFIUS. That committee has the power to block deals if it deems them a threat to national security or U.S. “technological superiority.” Those who don’t submit to the review could face fines as high as their proposed investments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.